Market Overview

UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities

Related ALKS
Barclays Adjusts Price Targets On AK Steel, CONSOL Energy And Others
Barclays Sees 32% Upside In Alkermes Shares, Says 2016 Vivitrol Sales 'Could Easily Top Guidance'
Good Enough - Cramer's Mad Money (7/26/16) (Seeking Alpha)

Morgan Stanley upgraded Alkermes plc (NASDAQ: ALKS) from Equal-weight to Overweight and raised the price target from $21.00 to $26.00.

Morgan Stanley noted, "We anticipate improving investor perception as Alkermes transitions from being an outsourced drug delivery tech co. to an innovation engine with higher-value internal candidates. … We added a key new pipeline drug (3831 for schizophrenia) due to new disclosure Jan. 4, and we have greater conviction that Alkermes can develop new drugs to offset patent expirations in 2019 and beyond."

Alkermes plc closed at $21.61 on Wednesday.

Latest Ratings for ALKS

Jul 2016Cowen & CompanyUpgradesOutperformMarket Perform
Jul 2016BarclaysMaintainsOverweight
May 2016Evercore ISI GroupInitiates Coverage onBuy

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (ALKS)

View Comments and Join the Discussion!